EphB4-ephrin-B2 are targets in castration resistant prostate cancer
EphB4 and ephrin-B2 receptor ligand pair is induced in PTEN null prostate cancer, which significantly contributes to the tumor initiation. Secondly, EphB4-ephrin-B2 pathway continue to promote tumor progression even in androgen deprivation and thus hormone refractory tumor. EphB4-ephrin-B2 may be candidates for precision medicine with biomarker-based patient selection with and without concurrent standard of care.
Authors
- Mitchell E. Gross (ORCID: https://orcid.org/0000-0002-1691-921X)
- Anthony B. El-Khoueiry (ORCID: https://orcid.org/0000-0002-9053-3841)
- Shaobing Zhang (ORCID: https://orcid.org/0000-0002-8014-536X)
- Bodour Salhia
- Imran Siddiqi (ORCID: https://orcid.org/0000-0001-8083-9639)
- Akash Sali (ORCID: https://orcid.org/0000-0003-1404-7347)
- Grace X. Li (ORCID: https://orcid.org/0000-0003-2242-2020)
- Binyun Ma (ORCID: https://orcid.org/0000-0003-3363-7174)
- Sarmad Sadeghi (ORCID: https://orcid.org/0000-0003-2654-1991)
- Ren Liu (ORCID: https://orcid.org/0000-0003-1809-1441)
- Parkash S. Gill (ORCID: https://orcid.org/0000-0003-4919-7337)
Institutions
- University of Southern California (US)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1038/s41416-025-02942-5
- Citations
- 2
- Primary Topic
- Axon Guidance and Neuronal Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.82